Anti-angiogenic therapy for high-grade glioma

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 11, 2018, Pages

  Ameratunga, Malaka ^a   Pavlakis, Nick ^b   Wheeler, Helen ^b   Grant, Robin ^c   Simes, John ^d   Khasraw, Mustafa ^d  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; CILENGITIDE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LOMUSTINE; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DACARBAZINE; IRINOTECAN; MONOCLONAL ANTIBODY; SNAKE VENOM;

ANTIANGIOGENIC ACTIVITY; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY; CONTROLLED ORAL WORD ASSOCIATION TEST; DETERIORATION FREE SURVIVAL; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG MECHANISM; GLIOBLASTOMA; GLIOMA; GLUCOSE METABOLISM; HOPKINS VERBAL LEARNING TEST; HUMAN; HYPERTENSION; MEDIAN SURVIVAL TIME; MINI MENTAL STATE EXAMINATION; MOLECULARLY TARGETED THERAPY; NEOADJUVANT CHEMOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRAIL MAKING TEST; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; WOUND COMPLICATION; ANALOGS AND DERIVATIVES; BRAIN TUMOR; CHEMICALLY INDUCED; META ANALYSIS; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PROTEINURIA; TUMOR RECURRENCE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BRAIN NEOPLASMS; CAMPTOTHECIN; DACARBAZINE; GLIOBLASTOMA; HUMANS; HYPERTENSION; IRINOTECAN; LOMUSTINE; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGRESSION-FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SNAKE VENOMS; TEMOZOLOMIDE;

EID: 85057463241     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008218.pub4     Document Type: Review

References (68)

1. Balana C, De Las Penas R, Sepulveda JM, Gil-Gil MJ, Luque R, Gallego O, et al. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma:the GENOM 009 randomized phase II trial. Journal of Neurooncology 2016;127:569-79. [DOI: 10.1007/s11060-016-2065-5]9449177
2. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomised trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of Clinical Oncology 2013;31(26):3212-8. 9449179
3. Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. Annals of Oncology 2014;25:1442-7. [DOI: 10.1093/annonc/mdu148]9449181
4. Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine 2014;370(8):709-22. [DOI: 10.1056/NEJMoa1308345]9449183
5. Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot Ol, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio Trial. Journal of Clinical Oncology 2015;33(25):2735-44. 9449184
6. Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, et al. Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma.. Journal of Clinical Oncology 2015;33(19):2166-75. 9449185
7. Armstrong TS, Won M, Wefel JS, Gilbert MR, Pugh SL, Brachman D, et al. Comparative impact of tumor and treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled In RTOG 0825. Journal of Clinical Oncology 2013; Vol. 31 Suppl 15. 9449187
8. Gilbert MR, Dignam J, Armstrong TS, Wefel JS, Blumenthal D, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine 2014;370(8):699-708. [DOI: 10.1056/NEJMoa1308573]9449188
9. Wefel J, Pugh S, Armstrong T, Gilbert M, Won M, Wendland M, et al. Neurocognitive function outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825. Journal of Clinical Oncology 2013; Vol. 31 Suppl 15. 9449189
10. Herrlinger U, Schaefer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: The Randomized GLARIUS Trial.. Journal of Clinical Oncology 2016;34(14):1611-19. 9449191
11. Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, et al. A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. Clinical Cancer Research 2015;21(16):3610-8. [DOI: 10.1158/1078-0432.CCR-14-3220]9449193
12. Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-Oncology 2015;17(5):708-17. 9449195
13. Stupp R, Hegi ME, Gorlia T, Erridge S, Perry J, Hong Y-K, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology 2014;15:1100-8. 9449197
14. Taal W, Oosterkamp HM, Walenkamp A, Dubbink H, Beerepoot LV, Hanse M, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The Lancet Oncology 2014;15(9):943-53. 9449199
15. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. New England Journal of Medicine 2017;377(20):1954-63. [DOI: 10.1056/NEJMoa1707358]9449201
16. Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, et al. AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro-Oncology 2016;18(9):1304-12. [DOI: 10.1093/neuonc/now035]9449203
17. Duerinck J, Du Four S, Vandervorst S, D'Haene N, Le Mercier M, Michotte A, et al. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. Journal of Neurooncology 2016;128:147-55. [DOI: 10.1007/s11060-016-2092-2]9449205
18. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology 2009;27(28):4733-40. 9449207
19. Kreisl TM, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology 2009;27(5):740-5. 9449209
20. Lombardi G, De Salvo GL, Ruda R, Franceschi E, Eoli M, Faedi M, et al. Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS). Journal of Clinical Oncology. May 2018; Vol. 36, issue 15:2047. 9449211
21. Van Den Bent M, Klein M, Smits M, Reijneveld JC, Idbaih A, Clement P, et al. Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. Journal of Clinical Oncology 2017; Vol. 35 Suppl 15. [DOI: 10.1200/JCO.2017.35.15_suppl.2009]9449213
22. Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, et al. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Annals of Oncology 10 Apr 2018;29(6):1423-30. 9449215
23. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ (Clinical Research edition) 2001;323(7306):224-8.
24. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Current Opinion in Neurology 2009;22(6):633-8.
25. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology 2015;Suppl 4:iv1-iv62.
26. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloeguen Y, Cloughesy TF. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Current Neurology Neurosciences Reports 2013;13:347.
27. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972;34(2):187-220.
28. NIH-NIC . Common terminology criteria for adverse events (CTCAE v5.0). National Cancer Institute 2017.
29. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. Journal of the National Cancer Institute 1993;85(9):704-10.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
31. Fayers PM, Aaronson NK, Bjordal K, Grønvold M, Curran D, Bottomley A, EORTC Quality of Life Group. EORTC QLQ-C30 Scoring Manual. 3rd Edition. Brussels: European Organisation for Research and Treatment of Cancer, 2001. [ISBN: 2-9300-6416-1]
32. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis . Cell 1994;79(2):185-8.
33. Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro-oncology 2015;17(11):1504-13.
34. Field KM, King MT, Simes J, Espinoza D, Barnes EH, Sawkins K, et al. Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma. Journal of Neuro-oncology 2017;133(3):623-31.
35. Folkman J, Bach M, Rowe JW, Davidoff F, Lambert P, Hirsch C, et al. Tumor angiogenesis - therapeutic implications. New England Journal of Medicine 1971;285(21):1182-6.
36. Folkman J. What is the evidence that tumors are angiogenesis dependent?. Journal of the National Cancer Institute 1990;82(1):4-6.
37. Gasparini G, Longo R, Fanielli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges and open questions. Journal of Clinical Oncology 2005;23(6):1295-311.
38. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology 2005;23(5):1011-27.
39. Higgins JP, Thompson SG, Deeks JJ, Altman DG . Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
40. Higgins JP, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
41. Higgins JP, Deeks JJ, editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
42. Kerbel RS. Tumor angiogenesis. New England Journal of Medicine 2008;358:2039-49. [DOI: 10.1056/NEJMra0706596]
43. Khasraw M, Lassman A. Advances in the treatment of malignant gliomas. Current Oncology Reports 2010;12(1):26-33.
44. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;23(2):81.
45. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
46. Lombardi G, Pambuku A, Bellu L, Farina M, Della Puppa A, Denaro l, et al. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology 2017;111:94-102.
47. Louis DN, Perry A, Reifenberger G, von Deimling A, FigarellaBranger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System. Acta Neuropathology 2016;131(6):803-20. [DOI: 10.1007/s00401-016-1545-1]
48. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant gliomas. Journal of Clinical Oncology 1990;8(7):1277-80.
49. Machin D, Stenning SP, Parmar MKP. Thirty years of Medical Research Council randomized trials in solid tumors. Journal of Clinical Oncology 1997;9:100-14.
50. Mauer ME, Bottomley A, Taphoorn MJ. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in clinical trials and clinical practice. Current Opinion in Neurology 2008;21:741-53.
51. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82.
52. Mirimanoff R-O, Gorlia T, Mason W, Van den Bent MJ, Kortmann R-D, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of Clinical Oncology 2006;24(16):2563-9.
53. Parmar MKB, Torri V, Steward L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
54. Radbruch A, Lutz K, Wiestler B, Bäumer P, Heiland S, Wick W, et al. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro-oncology 2011;14(2):222-9.
55. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
56. Scaringi C, Enrici RM, Minniti G. Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets and Therapy 2013;6:1079-95.
57. Sivakumar B, Harry LE, Paleolog EM. Modulating angiogenesis. JAMA 2005;292(8):972-7.
58. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005;352:987-96.
59. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. Journal of Clinical Oncology 2007;25(26):4127-36.
60. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 2009;10(5):459-66.
61. Taphoorn MJB, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. European Journal of Cancer 2010;46(6):1033-40.
62. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000;92(3):205-16.
63. Vredenburgh J, Cloughesy T, Samant M, Prados M, Wen P, Mikkelson T, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN Study. The Oncologist 2010;15(12):1329-34.
64. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology 2010;28(11):1963-72.
65. Yan H, Parsons DW, Jin G, McLendon R, Ahmed Rasheed B, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine 2009;360:765-73.
66. Zebrowski BK, Yano S, Liu WB, Shaheen RM, Hicklin DJ, Putnam JB, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clinical Cancer Research 1999;5(11):3364-68.
67. Khasraw M, Lassman A, Wheeler H, Pavlakis N. Anti-angiogenic therapy for high grade glioma. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008218]
68. Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade glioma. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD008218.pub3]